In the intricate world of neuropharmacology, the standard approach to clinical trials has long relied on a deceptively simple premise: administer a fixed dose of a drug to a diverse group of individuals, then average their outcomes to declare efficacy or failure. Yet, a provocative new study challenges this fundamental assumption, revealing that such averaging may obscure critical biological variables—most strikingly, sex and hormonal cycles—that profoundly influence drug dynamics. The research, led by Professor Illana Gozes at Tel Aviv University and published in Genomic Psychiatry, casts a spotlight on davunetide, a neuroprotective peptide that has long held promise for treating tauopathies yet consistently failed to show efficacy in large-scale trials.
Davunetide, also known by its peptide acronym NAP, emerged as a hopeful candidate in the treatment of neurodegenerative diseases characterized by tau protein malfunction, such as Alzheimer’s disease and progressive supranuclear palsy (PSP). This peptide works by stabilizing microtubules—microscopic structural elements critical for maintaining the integrity and function of neural cells. Despite its theoretical appeal, davunetide’s largest clinical trials, particularly in PSP, ended in disappointment, with no clear evidence of therapeutic benefit. However, Gozes and colleagues suspected that the conventional analyses might have missed key sex-based pharmacokinetic distinctions.
What set this investigation apart was its focus on the nuanced biological rhythms that differentiate female subjects. The researchers employed an innovative technique: tagging davunetide with a fluorescent marker to track its absorption and distribution in live mice. Crucially, they didn’t treat female mice as a homogenous group but instead monitored their estrous cycle phases—a rodent’s hormonal cycle analogous to the menstrual cycle in humans. This methodological rigor revealed a striking pattern: female mice during high-estrogen phases (proestrus and estrus) exhibited significantly higher concentrations of davunetide in their brain regions compared to males and to females in low-estrogen phases.
The statistical robustness of these findings was remarkable. In the proestrus phase, for example, differences in brain uptake between males and females were not only substantial but also highly statistically significant, with p-values reaching as low as 0.000004 for head-to-body drug concentration ratios. This suggests that estrogen levels directly impact the bioavailability of davunetide within the central nervous system. The implication is profound—hormonal fluctuations modulate the drug’s journey across the blood-brain barrier, thus influencing its therapeutic potential in ways that conventional trial designs do not account for.
Additional experiments reinforced this conclusion. When female mice were pooled regardless of estrous phase, they still showed consistently higher brain uptake than their male counterparts, underscoring an intrinsic sex difference. Intriguingly, systemic (body-wide) drug concentrations told a different story than cerebral concentrations, hinting that factors regulating central nervous system penetration, such as blood-brain barrier permeability, are under hormonal governance. This uncoupling between peripheral circulation and central uptake complicates the pharmacodynamics and calls for more tailored administration protocols.
Recognizing the translational limitations of rodent models, the authors extended their inquiry to a small human dataset from a past pharmacokinetic study on intranasal davunetide involving healthy adults. Though limited by sample size—only two men and six women—the data hinted at a congruent pattern. Female subjects tended to reach peak nasal and cerebral drug concentrations that were more than double those observed in males. Conversely, males exhibited a markedly longer half-life of the drug, indicating slower clearance. While the sample posed constraints on statistical power, the sex-specific tendencies matched the rodent model’s reflections, reinforcing the biological relevance of these dynamics in humans.
At the biological mechanistic level, the study elucidates a network of interactions linking estrogen, microtubule stability, and blood-brain barrier function. Estrogen is known to modulate vascular tone and endothelial integrity, properties that govern the barrier controlling molecular traffic into the brain. The ADNP protein, from which davunetide is derived, itself undergoes regulation by estrous cycling and reciprocally influences sex hormone pathways. This molecular interplay suggests that davunetide’s neuroprotective effects could hinge critically on hormonal context, complicating straightforward dose-response relationships and potentially explaining the lackluster performance in unstratified clinical trials.
One particularly compelling and somber observation emerged from studies on elderly mice: male rodents exhibited increased mortality during procedures, spotlighting inherent sex differences in vulnerability at advanced ages. Such physiological disparities underscore the urgency of incorporating sex as a biological variable in preclinical and clinical neuropharmacology. The traditional approach, which effectively treats male and female as interchangeable in therapeutic contexts, now seems inadequate and possibly detrimental.
The authors are forthcoming about the limitations of their work. Sample sizes, particularly in human cohorts, remain small and exploratory. Estrous cycle staging involves subjective assessments that may introduce variability, and the studies were not designed to establish definitive therapeutic guidelines. Yet, the methodological transparency and measured interpretation lend credibility to their central argument: averaging out sex and hormonal differences in drug evaluation risks discarding biologically significant variability.
Beyond davunetide, the broader implications of these findings could reverberate throughout neurodegenerative disease research. Alzheimer’s disease disproportionately affects women, manifesting roughly twice as frequently as in men. If sex and hormonal milieu influence neuroprotective agent bioavailability and efficacy, clinical trial failures may partially reflect flawed design rather than true pharmacological ineffectiveness. Integrating precise tracking of sex-specific biology, including hormonal states, may unlock previously obscured therapeutic windows and rescue promising candidates from premature dismissal.
Ultimately, this study challenges a long-standing dogma in drug development: that a “one-size-fits-all” approach to dosing and efficacy assessments is appropriate. Instead, it posits a complex, dynamic landscape where individual biology—including transient hormonal cycles—modulates drug behavior with profound clinical implications. Moving forward, therapeutic strategies must embrace this complexity, aiming to tailor interventions not just to the person but sometimes even to the time within their biological cycle.
Professor Gozes and her team underscore this shift as not merely scientific but ethical: patients deserve precision in medication that respects biological individuality rather than expecting uniform outcomes. The path ahead demands more nuanced clinical trial designs, incorporating sex-specific analyses and hormonal monitoring, to truly optimize neuroprotective treatments and fulfill their potential to alter the trajectory of devastating tauopathies.
As neuroscience continues to unravel the layered intricacies of human biology, this study provokes a vital reconsideration of how we evaluate drugs entering the brain. The fluid interplay between sex hormones, vascular systems, and neuronal scaffolds offers a persuasive argument that “the average patient” is an abstraction—one that risks blunting medical innovation. Therefore, the research presented in Genomic Psychiatry is not just a technical insight into a single peptide’s pharmacokinetics; it is a rallying call to recalibrate our scientific and clinical frameworks around the nuanced realities of sex and hormone-dependent drug bioavailability.
Subject of Research: People
Article Title: Intranasal bioavailability is estrous-cycle regulated: Davunetide as a case study
News Publication Date: 16 June 2026
Web References:
https://doi.org/10.61373/gp026r.0039
References:
Blatt J, Guz LS, Shabat D, Gozes I. Intranasal bioavailability is estrous-cycle regulated: Davunetide as a case study. Genomic Psychiatry 2026. DOI: https://doi.org/10.61373/gp026r.0039. Epub 2026 Jun 16.
Image Credits: Illana Gozes
Keywords
Sex differences, Hormonal regulation, Estrous cycle, Davunetide, ADNP peptide, Blood-brain barrier, Neuroprotection, Tauopathies, Alzheimer’s disease, Pharmacokinetics, Intranasal delivery, Microtubule stabilization
Tags: Alzheimer’s disease peptide therapydavunetide neuroprotective peptidehormonal cycle impact on medicationmicrotubule stabilization in neuronsneuropharmacology clinical trial variabilitypeptide drug failure analysispersonalized medicine in neurologypharmacokinetics of neurodegenerative drugsprogressive supranuclear palsy drug trialssex differences in drug responsesex-based analysis in clinical studiestauopathies treatment research
